This is the authors' abstract. We don't add key points for this paper.
In 1988, the first IVF and embryo transfer infant was born on the Chinese mainland. For over 30 years, ART in China has developed rapidly. At present, the number of ART cycles (including IVF and artificial insemination) has exceeded 1 million per year in China, accounting for ∼3% of the total number of ART cycles in globe (Bai et al., 2020). The number of ART babies exceeds 300 000 per year in China, accounting for ∼3% of the total number of births nationwide. The development of reproductive medicine technologies has made remarkable contributions to promoting family happiness and social harmony. In recent years, the aging population has been continuously intensifying, and the average number of women of childbearing age in China will decrease by 2 million per year in the next 10 years. Furthermore, the infertility rate has increased to 17.6% due to complex factors, such as delayed reproductive age and declining fecundity (Cox et al., 2022). In addition, the number of adverse pregnancy outcomes, such as miscarriage, fetal malformations, etc., exceeds 2 million annually. However, the success rate of ART is limited and has entered a bottleneck period. From a global perspective, the overall success rate of female infertility treatment is <40% (Qiao et al., 2021).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Kong et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: